Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data
SDAI-LDA is associated with more structural damage over 2 years than any of the definitions of remission. It also allows substantial disease impact to go unchecked and uncontrolled. Physicians should strive for remission whenever possible and safe while also taking into account the different individual disease activity parameters included in the adopted definition.
Authors
- Ricardo J O Ferreira (ORCID: https://orcid.org/0000-0002-2517-0247)
- Paco M J Welsing (ORCID: https://orcid.org/0000-0003-2361-2803)
- Cátia C. M. Duarte (ORCID: https://orcid.org/0000-0001-9327-6935)
- Pedro Machado (ORCID: https://orcid.org/0000-0002-8411-7972)
- Laure Gossec (ORCID: https://orcid.org/0000-0002-4528-310X)
- José António Pereira da Silva (ORCID: https://orcid.org/0000-0002-2782-6780)
- Désirée M F M van der Heijde (ORCID: https://orcid.org/0000-0002-5781-158X)
- Johannes W G Jacobs
Institutions
- Inserm (FR)
- Leiden University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Sorbonne Université (FR)
- Lisbon School of Design (PT)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- Nursing Research, Innovation and Development Centre of Lisbon (PT)
- University College London (GB)
- Escola Superior de Enfermagem de Coimbra (PT)
- University of Coimbra (PT)
Publication Details
- Journal
- RMD Open
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-004387
- Citations
- 4
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Pfizer